Table 3.
Impact of GLP-1RAs on clinical outcomes according to baseline combination use with SGLT2is
| Outcomes | Baseline SGLT2i Use | Individual Trials | Meta-analysis [48] | |
|---|---|---|---|---|
| AMPLITUDE-O [47] (Epfegrenatide) | Harmony Outcomes [48] (Albiglutide) | |||
| MACE | With SGLT2i |
0.70 (0.37–1.30) |
0.89 (0.45–1.77) |
0.78 (0.49–1.24) |
| Without SGLT2i |
0.74 (0.58–0.94) |
0.78 (0.67–0.90) |
0.77 (0.68–0.87) |
|
| HHF | With SGLT2i |
0.23 (0.05–0.97) |
0.50 (0.12–2.08) |
0.34 (0.12–0.96) |
| Without SGLT2i |
0.70 (0.42–1.17) |
0.72 (0.54–0.97) |
0.72 (0.55–0.92) |
|
| Composite kidney events* | With SGLT2i |
0.52 (0.33–0.83) |
N/A | N/A |
| Without SGLT2i |
0.70 (0.59–0.83) |
N/A | N/A | |
Data are presented as hazard ratio (95% confidence interval)
GLP-1RA glucagon-like peptide-1 receptor agonist, HHF heart failure hospitalization, MACE major adverse cardiovascular events, N/A not available, SGLT2i sodium-glucose cotransporter 2 inhibitor
*Including macroalubuminuria